Keywords: update, roche, rituxan, shows, improvement, ra, reported
UPDATE: Roche's Rituxan shows improvement in RA
Article | 18 April 2005
As reported briefly last week, Rituxan/MabThera (rituximab) Roche, Genentech and Biogen Idec's drug for non-Hodgkin's lymphoma, has demonstrated that ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
